Study #2024-1689
A phase 2 study of WU-CART-007, an anti-CD7 allogeneic CAR-T cell therapy in patients with relapsed or refractory T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma
MD Anderson Study Status
Enrolling
Treatment Agent
WU-CART-007
Description
The main purpose of this study is to evaluate the Composite Complete Remission Rate (CRc) of WU-CART-007 in Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) patients and to evaluate the efficacy of WU-CART-007 to induce complete Minimum Residual Disease (MRD) negative response
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
T-cell Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Study phase:
Phase II
Physician name:
Elias Jabbour
Department:
Leukemia
For general questions about clinical trials:
1-855-401-1031
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.